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The  discovery  by  Yamanaka  and  Takahashi  (2006)  that 
over-expression of key embryonic stem cell transcription 
factors  can  drive  the  emergence  of  a  pluripotent  cell 
population  from  adult  fibroblasts  has  generated  new 
excitement in the  field of  stem cell therapy, offering to 
overcome  technical  and  ethical  hurdles  in  generating 
patient  specific  cells  for  therapeutic  and  research 
applications.  
 
Induced pluripotent stem-like (iPS) cells have now been 
derived from multiple source tissues, and demonstrated to 
contribute to all tissue lineages when injected into mouse 
blastocysts  -  the  practical  definition  of  pluripotency 
(Reviewed  in  Jaenisch  and  Young,  2008).  Proof  of 
principle experiments from Jaenisch and colleagues have 
demonstrated  the  potential  to  reprogram  and  genetically 
correct subject-derived tissue in a humanized sickle cell 
anemia  mouse  model,  achieving  replacement  of  the 
diseased hematopoietic progenitor niche by transplantation 
with  hematopoietic  progenitors  obtained  by  in  vitro 
differentiation  from  autologous  iPS  cells  (Hanna  et  al, 
2007). Refinement of this technology promises to provide 
new  opportunities  for  development  of  more  accurate 
models of human disease for research, and potentially new 
therapeutic technology to repair tissue damage and genetic 
deficiencies in human patients. 
 
Cell  fusion  and  nuclear  transfer  experiments  suggested 
that  differentiated  cells  can  be  reprogrammed  to  an 
embryonic-like  state  using  components  present  in 
pluripotent  cells  (Do  et  al,  2004).  The  concept  of 
reprogramming  also  exists  in  accumulated  research  into 
cancer development; tumor formation appears to involve a 
‘de-differentitation’ of post-mitotic cells into a progenitor, 
cycling  state.  Higher  grade  tumors  appear  less 
differentiated morphologically and genetically, and begin 
to  resemble  embryonic  stem  cells  in  their  transcriptome 
content (Ben-Porath et al, 2008). Proto-oncogene c-Myc is 
also  a  key  driver  of  stem  cell  proliferation,  and  the  re-
activation  of  embryonic  gene  expression  programs 
underlies much of the metastasis of tumors in vivo (Yang 
et al, 2006).   
 
Tumor  development  involves  the  gradual  attainment  of 
multipotency,  the  ability  to  differentiate  into  multiple 
lineages.  A  small  population  of  CD44-high/CD24-low 
cells can be isolated from mammary epithelial tumors that 
are  capable  of  seeding  new  tumors  when  injected  into 
mice (Mani et al, 2008). These ‘cancer stem cells’ may be 
responsible for much of the tumor capacity to metastasize, 
and perhaps repopulate after chemotherapy. Conspicuous 
similarities  between  reprogramming  and  tumor 
development seem likely to provide new insights into how 
cancers might arise, be tackled, and how reprogramming 
therapies may avoid enhancing tumor risk.  
 
A range of protein factors have now been identified that 
can  be  combined  to  reprogram  somatic  cells  into  iPS 
cells.  Key  proteins  appear  to  be  embryonic  stem  cell 
transcription factors POUF51 and SOX2, with MYC and 
KLF  family  members  enhancing  the  efficiency  of 
reprogramming,  although  the  exact  combination  of 
factors  necessary  may  vary  with  the  somatic  tissue 
chosen.  Common  technical  difficulties  remain  however 
in  that  these  proteins  must  be  expressed  at  high  copy 
number and often integrated into the somatic cell genome 
to  achieve  expression  over  the  necessary  timeframe. 
Given  the  proliferation  inducing  properties  of  this 
combination of factors, much focus has converged upon 
means to transiently express and remove the necessary 
proteins in order to leave the iPS genome as pristine as 
possible and to prevent the anticipated increased tumor 
propensity  in  cells  containing  multiple  copies  of 
oncogene  cDNA  (Okita  et  al,  2008;  Lyssiotis  et  al, 
2009).  New  reports  suggest  that  the  expression  of 
microRNAs  can  efficiently  reprogram  somatic  cells, 
potentially without requiring genomic integration (Lin et 
al, 2008; Judson et al, 2009).  
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miRNAs are broad regulators of messenger RNA stability, 
interacting with many mRNA targets within the cellular 
transcriptome.  The  breadth  of  miRNA  regulation  makes 
these small RNAs powerful regulators of cell state; tumor 
formation often involves down regulation of the cellular 
miRNA  component,  avoidance  of  miRNA  targeting  by 
mRNAs  and  in  some  cases  selection  for  expression  of 
particular  miRNAs  that  enhance  proliferation  or  cell 
survival (reviewed in Ventura and Jacks, 2009). The small 
footprint  of  miRNAs  and  siRNAs,  and  the  ability  to 
effectively deliver transient functionality without need for 
genomic integration, makes them good candidates for use 
in  reprogramming.  Indeed  an  early  cDNA  screen 
identifying  factors  for reprogramming  human  fibroblasts 
identified  LIN28B  as  a  reprogramming  protein,  the 
primary  function  of  which  (in  embryonic  stem  cells) 
appears to be in the inhibition of miRNA processing for 
the anti-proliferation Let-7 family of miRNAs (specifically 
those containing the trinucleotide ‘CCC’ motif within the 
miRNA  terminal  loop)(Yu  et  al,  2007).  This  early 
indication  of  the  importance  of  miRNAs  to 
reprogramming has further been expanded upon through 
the observation that c-MYC activity can be substituted by 
members of the mouse specific miR-290-295 cluster that 
contain the seed sequence AAGUGCA (which is partially 
shared by members of the miR-17-92 family)(Judson et al, 
2009). Accumulating evidence indicates that the common 
seed of the miR-17-92 cluster drives the G1 to S transition 
that  is  fundamental  for  ES  self-renewal  and  cell 
proliferation  (Wang  et  al,  2008).  Additionally,  miR-302 
(seed  AGUGCUU-)  enhances  the  expression  of 
reprogramming  factors  in  human  cancer  cell  lines  and 
appears to reprogram these cells into a stem-like state (Lin 
et al, 2008). Mir-145, in contrast, has been demonstrated 
to  repress  key  reprogramming  genes  OCT4,  SOX2  and 
KLF4  in  vivo,  but  notably  is  often  down  regulated  in 
colorectal  tumor  samples,  indicating  a  further  potential 
route to a stem-cell like state through intervention at the 
miRNA level (Xu et al, 2009).  
 
The  efficiency  of  reprogramming  techniques  is  low 
(commonly less than 0.001% of cultured cells are capable 
of forming embryonic stem cell-like colonies), and much 
remains  to  be  learned  about  the  stability  of  re-
differentiated reprogrammed cells over time in vivo. Key 
in developing this technology will be an understanding of 
the  core  biology  of  how  reprogramming  factors  impact 
upon cellular gene expression networks, and the role of 
small RNAs in regulating these gene expression networks.  
 
Antagomirs directed against key miRNAs in immortalized 
cells  have demonstrated researcher’s ability to  modulate 
proliferation networks in tumors through delivery of small 
oligonucleotides  (e.g.,  Fontana  et  al,  2008).  Delivery  of 
multiple small oligonucloetides that mimic miRNAs may 
more efficiently modulate cellular gene expression so as to 
both  inhibit  proliferation  genes  and  enhance  non-
proliferation gene expression – in essence both taking the 
foot  off  the  gas,  and  applying  the  brakes.  Such 
combinatorial  therapy  might  potentiate  the  effect  of 
cooperative miRNAs, and be more resistant to ‘escape’ by 
tumor  cells  that  can  overcome  a  single  chemical  agent. 
Furthermore,  miRNA-orientated  approaches  may  be 
necessary  to  overcome  the  inherent  canalization  of 
differentiated  cells  prior  to  full  induction  of  progenitor 
gene expression programs – releasing the brakes to allow 
the  car  to  be  pushed.  Annotation  of  important  miRNA 
targets will aid in the rational design of such approaches, 
but  will  also  require  a  re-evaluation  of  much  existing 
interaction data with regards to identifying targets that are 
functionally  relevant  nodes  in  specific  tissues  and 
biological networks.  
 
Research  into  the  basic  biology  of  cancer,  and  an 
understanding of embryonic stem cells, has synergized in 
the burgeoning field of somatic cell reprogramming. The 
rapid advancements in miRNA research over the past ten 
years represent one of the first applications of truly holistic 
systems biology approaches to representing the biological 
networks of a cell. There exist now stirring opportunities 
to  apply  these  advances  to  the  specific  manipulation  of 
cellular gene expression programs, and towards genuinely 
groundbreaking therapeutic technologies.  
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